Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis

Exclusion Criteria

• •Patients with concomitant allergic rhinitis, demonstrated by positive skin prick test (Hal reagents) and/or immunoglobins E in blood. \*
• •Patients with structural abnormalities: nasal polyps, severe septal deviation (septum reaching concha inferior or lateral nasal wall), septal perforation, hypertrophy of the inferior turbinates.
• •Patients with local allergic rhinitis (LAR) or entopy.
• •Systemic steroid treatment less than 4 weeks before the inclusion in the study, nasal steroid spray less than 4 weeks before the inclusion, oral leukotriene antagonists or long-acting antihistamines less than 2 weeks before the inclusion.
• •Inability of the patient to stop taking medication affecting nasal function like ß-blockers.
• •History of prolonged use or abuse of decongestant nasal spray like xylometazoline spray and/or use or abuse of decongestive oral medication.
• •Evidence of infectious rhinitis/rhinosinusitis or common cold within 4 weeks prior to inclusion.
• •Pregnancy or lactation. \*\*
• •Any disorder of which might compromise the ability of a patient to give truly informed consent for participation in this study.
• •Enrollment in other investigational drug trial(s) or receiving other investigational agent(s) for any other medical condition.
• •Contra-indications for the use of local anesthesia (cocaine 5%).
• •Smoking or occupational exposure to irritants (like hypochlorite, persulfates, isocyanates).
• •Nasal malignancies or severe comorbidity like granulomatosis or vasculitis.